Cyclodextrin-impregnated masks to prevent the transmission of coronavirus
CycloLab’s submission to InnoCentive Challenge 9934291 – New Technologies to Prevent the Transmission of Coronavirus led to a favorable evaluation.
Tag: HPBCD
Cyclodextrin counteracts obesity associated with various diseases including susceptibility for Covid-19
Obesity has become a worldwide health crisis and is associated with a plethora of comorbidities. Cardiovascular disease (CVD) and type
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Resveratrol analogs solubilized by HPBCD show antimicrobial and anti-inflammatory effects
Scientific Report published on the recent results of Faculty of Dentistry, National University of Singapore. [1] Resveratrol (RES) is a
Ototoxicity of cyclodextrin derivatives
There are two possible mechanisms behind the ototoxicity of 2-hydroxypropyl-β-cyclodextrin (HPBCD) treatment. One is : the possible interaction of HPBCD
Cyclodextrin to prevent abdominal aortic aneurysm
The scientists at University of Michigan Medical Center, Ann Arbor, MI published on a new application of hydroxypropyl beta-cyclodextrin (HPβCD)
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
Use of cyclodextrins as agrochemical delivery system
ADAMA MAKHTESHIM LTD. (Israel) filed a PCT patent application (WO2020084572) that was recently published. The invention relates to preparation and use
Cyclo Therapeutics reports international patent application for treating Alzheimer’s
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.